Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Progranulin Levels in Plasma and Cerebrospinal Fluid in Granulin Mutation Carriers

Open access
Meeter, Lieke H.H., Patzke, Holger, Loewen, Gordon, Dopper, Elise G.P., Pijnenburg, Yolande A.L., van Minkelen, Rick, van Swieten, John C. · 2016 · Dementia and Geriatric Cognitive Disorders Extra

Abstract

Background: Pathogenic mutations in the granulin gene (GRN) are causative in 5-10% of patients with frontotemporal dementia (FTD), mostly leading to reduced progranulin protein (PGRN) levels. Upcoming therapeutic trials focus on enhancing PGRN levels. Methods: Fluctuations in plasma PGRN (n = 41) and its relationship with cerebrospinal fluid (CSF, n = 32) and specific single nucleotide polymorphisms were investigated in pre- and symptomatic GRN mutation carriers and controls. Results: Plasma PGRN levels were lower in carriers than in controls and showed a mean coefficient of variation of 5.3% in carriers over 1 week. Although plasma PGRN correlated with CSF PGRN in carriers (r = 0.54, p = 0.02), plasma only explained 29% of the variability in CSF PGRN. rs5848, rs646776 and rs1990622 genotypes only partly explained the variability of PGRN levels between subjects. Conclusions: Plasma PGRN is relatively stable over 1 week and therefore seems suitable for treatment monitoring of PGRN-enhancing agents. Since plasma PGRN only moderately correlated with CSF PGRN, CSF sampling will additionally be needed in therapeutic trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000447738

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 PGRN levels in plasma and CSF. PGRN in plasma from healthy controls (n = 29), presymptomatic GRN mutation carriers (n = 28) and GRNpatients (n = 7) (a) and in CSF from healthy controls (n = 12), presymptomatic GRN mutation carriers (n = 16) and GRN patients (n = 7) (b). Each individual is represented as a data point and labeled by type of mutation. Horizontal lines are median plasma levels per group.
Fig. 1 PGRN levels in plasma and CSF. PGRN in plasma from healthy controls (n = 29), presymptomatic GRN mutation carriers (n = 28) and GRNpatients (n = 7) (a) and in CSF from healthy controls (n = 12), presymptomatic GRN mutation carriers (n = 16) and GRN patients (n = 7) (b). Each individual is represented as a data point and labeled by type of mutation. Horizontal lines are median plasma levels per group.CC BY-NC-ND · PubMed Central
Fig. 2 PGRN levels as a function of age. Scatterplots of PGRN levels in plasma (a) and CSF (b) by age at collection in healthy controls (squares), presymptomatic GRNmutation carriers (triangles) and GRN patients (diamonds). To prevent disclosure of genetic status, a 23-year-old subject was excluded from the graph (but not from the analyses).
Fig. 2 PGRN levels as a function of age. Scatterplots of PGRN levels in plasma (a) and CSF (b) by age at collection in healthy controls (squares), presymptomatic GRNmutation carriers (triangles) and GRN patients (diamonds). To prevent disclosure of genetic status, a 23-year-old subject was excluded from the graph (but not from the analyses).CC BY-NC-ND · PubMed Central
Fig. 3 Correlation plasma versus CSF PGRN. Scatterplot of the correlation (rs = 0.80, p <0.001) between PGRN levels in plasma and CSF in 12 healthy controls (squares), 16 presymptomatic GRNmutation carriers (triangles) and 4 GRNpatients (diamonds).
Fig. 3 Correlation plasma versus CSF PGRN. Scatterplot of the correlation (rs = 0.80, p <0.001) between PGRN levels in plasma and CSF in 12 healthy controls (squares), 16 presymptomatic GRNmutation carriers (triangles) and 4 GRNpatients (diamonds).CC BY-NC-ND · PubMed Central
Fig. 4 Longitudinal plasma PGRN. PGRN levels over time in plasma of healthy controls (n = 19, squares), presymptomatic GRN mutation carriers (n = 18, triangles) and GRN patients (n = 4, diamonds). Each withdrawal is represented with a data point; lines connect data points of each individual. At the 12-hour time point, 3 data points are missing (all GRN patients).
Fig. 4 Longitudinal plasma PGRN. PGRN levels over time in plasma of healthy controls (n = 19, squares), presymptomatic GRN mutation carriers (n = 18, triangles) and GRN patients (n = 4, diamonds). Each withdrawal is represented with a data point; lines connect data points of each individual. At the 12-hour time point, 3 data points are missing (all GRN patients).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 92

Metadata

Authors
Meeter, L. H. H., Patzke, H., Loewen, G., Dopper, E. G. P., Pijnenburg, Y. A. L., van Minkelen, R., & van Swieten, J. C.
Affiliations
  • Erasmus MC (NL)
  • FORUM Pharmaceuticals (United States) (US)
  • Amsterdam Neuroscience (NL)
Venue
Dementia and Geriatric Cognitive Disorders Extra
Publisher
S. Karger AG
Published
2016-07-22
Volume
6
Issue
2
Pages
330-340
ISSN
1664-5464 (ISSN-L)
OpenAlex
W2487820682
Cited by
87
References
32
Citations by year
2026: 7 · 2025: 10 · 2024: 7 · 2023: 8 · 2022: 4 · 2021: 19 · 2020: 11 · 2019: 9 · 2018: 6 · 2017: 5 · 2016: 1
FWCI
5.26
Type
journal article
Language
en
Open access
Licence
Locations
  • Dementia and Geriatric Cognitive Disorders Extra (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
  • Pure Amsterdam UMC (submittedVersion, other-oa)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
  • RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
Funders
  • FORUM Pharmaceuticals
  • Alzheimer Nederland
Topics
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
progranulin, GRN mutations, frontotemporal dementia, mutation carriers, single nucleotide polymorphisms, treatment monitoring, biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Progranulin Levels in Plasma and Cerebrospinal Fluid in Granulin Mutation Carriers. https://app.cochat.ai/papers/10.1159/000447738
The paper
Meeter, L. H. H., Patzke, H., Loewen, G., Dopper, E. G. P., Pijnenburg, Y. A. L., van Minkelen, R., & van Swieten, J. C. (2016). Progranulin Levels in Plasma and Cerebrospinal Fluid in Granulin Mutation Carriers. Dementia and Geriatric Cognitive Disorders Extra. https://doi.org/10.1159/000447738

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.